$Telomir Pharmaceuticals (TELO.US)$ NEWS Telomir Pharmaceuti...
NEWS
Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.
Telomir Pharmaceuticals presents promising pre-clinical data on Telomir-1 at a National Press Club event, showcasing a 40% increase in telomerase activity and lengthening of telomeres in human cells. The company plans to initiate human clinical trials for osteoarthritis and veterinary trials in 2025 after pre-clinical studies in 2024.
Telomir-1 shows a 40% increase in telomerase activity and lengthens telomeres in human cells.
The presentation outlines pre-clinical endpoints for determining 'anti-aging' effects in dogs.
Human clinical trials for osteoarthritis and veterinary trials are planned for 2025.
Telomir Pharmaceuticals emphasizes transparency and commitment to sharing research data.
Dr. Chris Chapman and Dr. Michael Roizen lead the presentation at the National Press Club event.
Telomir-1's potential to combat age-related conditions is highlighted by the company.
Expert panel 'the GeorgeTown Group' contributes to shaping Telomir-1's research direction.
The presentation outlines pre-clinical endpoints for determining 'anti-aging' effects in dogs.
Human clinical trials for osteoarthritis and veterinary trials are planned for 2025.
Telomir Pharmaceuticals emphasizes transparency and commitment to sharing research data.
Dr. Chris Chapman and Dr. Michael Roizen lead the presentation at the National Press Club event.
Telomir-1's potential to combat age-related conditions is highlighted by the company.
Expert panel 'the GeorgeTown Group' contributes to shaping Telomir-1's research direction.
WASHINGTON, April 16, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc.(Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on Telomir-1 as a potential treatment for age-related conditions, today recapped its presentation of compelling pre-clinical data on Telomir-1 at a high-profile event hosted at the National Press Club in Washington, D.C., on April 15, 2024.
Dr. Chris Chapman, Co-founder, Chairman, CEO, President and Chief Medical Officer of Telomir, and Dr. Michael Roizen, special advisor to Telomir on age reversal, spearheaded the presentation, showcasing the remarkable prospects for Telomir- 1 to potentially allow the body to repair itself and mitigate effects typically associated with aging.
Dr. Chris Chapman, Co-founder, Chairman, CEO, President and Chief Medical Officer of Telomir, and Dr. Michael Roizen, special advisor to Telomir on age reversal, spearheaded the presentation, showcasing the remarkable prospects for Telomir- 1 to potentially allow the body to repair itself and mitigate effects typically associated with aging.
As part of its commitment to transparency and openness in sharing its research data, during the event, Drs. Chapman and Roizen presented company data that showed the effect of Telomir-1, a novel molecule designed to modulate telomerase activity and elongate telomeres. The data show that telomeres lengthened in vitro in human cells and telomerase activity increased by 40%.
The presentation also described demonstrable pre-clinical animal testing endpoints for determining Telomir-1’s potential for “age reversal” or “anti-aging” effects such as gait strength or weakness, joint damage assessment, dynamic weight bearing, clinical chemistry, hematology, telomere length and change in synovial fluids.
The presentation also described demonstrable pre-clinical animal testing endpoints for determining Telomir-1’s potential for “age reversal” or “anti-aging” effects such as gait strength or weakness, joint damage assessment, dynamic weight bearing, clinical chemistry, hematology, telomere length and change in synovial fluids.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
565Followers
65Following
3576Visitors
Follow